Market Cap 695.77M
Revenue (ttm) 0.00
Net Income (ttm) -69.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 626,100
Avg Vol 852,724
Day's Range N/A - N/A
Shares Out 62.46M
Stochastic %K 49%
Beta 1.63
Analysts Strong Sell
Price Target $19.33

Company Profile

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progr...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 293 4900
Address:
6005 Hidden Valley Road, Suite 110, Carlsbad, United States
BioResearcher
BioResearcher Jun. 15 at 5:52 PM
$LRMR LXEO spikes today. FA has a very small market size, but it seems there are more and more companies offer drugs in FA treatment. $LXEO and $DSGN and $BIIB are the 3 companies in addition to LRMR.
0 · Reply
Tripple0toMillion
Tripple0toMillion May. 20 at 10:30 PM
$DSGN $RKLB Rolling my 2k shares profits to $DSGN with PT 17+
0 · Reply
kenny91655
kenny91655 May. 19 at 7:50 PM
$DSGN Love it if it could get down to 7's
0 · Reply
laaarsas
laaarsas May. 19 at 12:49 PM
$DSGN why is stock down?
0 · Reply
SuperGreenToday
SuperGreenToday May. 19 at 12:55 AM
$DSGN Share Price: $10.70 Contract Selected: Dec 18, 2026 $10 Calls Buy Zone: $2.63 – $3.26 Target Zone: $4.47 – $5.46 Potential Upside: 60% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Arcides
Arcides May. 18 at 5:28 PM
$DSGN down 51% from premarket high
1 · Reply
Olivia_Strickland
Olivia_Strickland May. 18 at 4:35 PM
$DSGN down 26% on the morning and my scanner is calling it a "breakout," which at this point I'm just gonna assume is sarcasm. they dropped four-week Friedreich Ataxia data last night and the market's verdict is apparently "thanks but no thanks," because that's a $14 stock trading with a 10 handle on 7.8x avg vol. biotech data prints are the one place where I genuinely have no edge, but I do know what a -26% candle on the news day usually means for the rest of the week. anyone here actually read the readout and have a take on whether this is an overreaction or the start of a longer bleed? structure breaking on the chart: https://tapeboard.com/chart/DSGN?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=dsgn-bk-dn-chart
1 · Reply
Arcides
Arcides May. 18 at 3:43 PM
0 · Reply
laaarsas
laaarsas May. 18 at 3:32 PM
$DSGN Why down today?
0 · Reply
OptionRunners
OptionRunners May. 18 at 12:58 PM
$DSGN +10% on data
0 · Reply
Latest News on DSGN
Design Therapeutics Transcript: Status update

May 18, 2026, 8:00 AM EDT - 4 weeks ago

Design Therapeutics Transcript: Status update


Design Therapeutics Press release: Status update

May 18, 2026, 8:00 AM EDT - 4 weeks ago

Design Therapeutics Press release: Status update


Design Therapeutics Slides: Status update

May 18, 2026, 8:00 AM EDT - 4 weeks ago

Design Therapeutics Slides: Status update


Design Therapeutics reports Q1 EPS (29c), consensus (33c)

2026-04-28T20:46:16.000Z - 7 weeks ago

Design Therapeutics reports Q1 EPS (29c), consensus (33c)


Design Therapeutics Earnings Call Transcript: Q1 2026

Apr 28, 2026, 8:30 AM EDT - 7 weeks ago

Design Therapeutics Earnings Call Transcript: Q1 2026


Design Therapeutics Quarterly report: Q1 2026

Apr 28, 2026, 8:30 AM EDT - 7 weeks ago

Design Therapeutics Quarterly report: Q1 2026


Design Therapeutics Earnings release: Q1 2026

Apr 28, 2026, 8:30 AM EDT - 7 weeks ago

Design Therapeutics Earnings release: Q1 2026


Design Therapeutics Slides: Q1 2026

Apr 28, 2026, 8:30 AM EDT - 7 weeks ago

Design Therapeutics Slides: Q1 2026


Design Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 7 weeks ago

Design Therapeutics Proxy statement: Proxy filing


Design Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 7 weeks ago

Design Therapeutics Proxy statement: Proxy filing


Design Therapeutics management to meet with Oppenheimer

2026-04-16T19:41:28.000Z - 2 months ago

Design Therapeutics management to meet with Oppenheimer


Design Therapeutics management to meet with Oppenheimer

2026-04-16T19:40:17.000Z - 2 months ago

Design Therapeutics management to meet with Oppenheimer


Design Therapeutics management to meet with Oppenheimer

2026-04-02T14:43:30.000Z - 2 months ago

Design Therapeutics management to meet with Oppenheimer


Design Therapeutics initiated with a Buy at Jefferies

2026-03-16T00:15:04.000Z - 3 months ago

Design Therapeutics initiated with a Buy at Jefferies


Design Therapeutics reports Q4 EPS (27c), consensus (35c)

2026-03-09T20:16:56.000Z - 3 months ago

Design Therapeutics reports Q4 EPS (27c), consensus (35c)


Design Therapeutics Annual report: Q4 2025

Mar 9, 2026, 4:00 PM EDT - 3 months ago

Design Therapeutics Annual report: Q4 2025


Design Therapeutics Earnings release: Q4 2025

Mar 9, 2026, 4:00 PM EDT - 3 months ago

Design Therapeutics Earnings release: Q4 2025


Design Therapeutics Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Design Therapeutics Slides: Corporate presentation


Design Therapeutics initiated with an Outperform at Oppenheimer

2026-01-07T11:37:08.000Z - 5 months ago

Design Therapeutics initiated with an Outperform at Oppenheimer


Design Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 3:00 PM EST - 7 months ago

Design Therapeutics Slides: Corporate Presentation


Design Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 7 months ago

Design Therapeutics Earnings release: Q3 2025


Design Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 7 months ago

Design Therapeutics Quarterly report: Q3 2025


Design Therapeutics Appoints Justin Gover to Board of Directors

Sep 10, 2025, 4:01 PM EDT - 9 months ago

Design Therapeutics Appoints Justin Gover to Board of Directors


Design Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 6:00 PM EDT - 11 months ago

Design Therapeutics Earnings release: Q2 2025


Design Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 6:00 PM EDT - 11 months ago

Design Therapeutics Quarterly report: Q2 2025


Design Therapeutics Earnings release: Q1 2025

May 6, 2025, 6:00 PM EDT - 1 year ago

Design Therapeutics Earnings release: Q1 2025


Design Therapeutics Quarterly report: Q1 2025

May 6, 2025, 6:00 PM EDT - 1 year ago

Design Therapeutics Quarterly report: Q1 2025


Design Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Design Therapeutics Proxy statement: Proxy Filing


Design Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Design Therapeutics Proxy statement: Proxy Filing


Design Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Design Therapeutics Proxy statement: Proxy Filing


Design Therapeutics Earnings release: Q4 2024

Feb 10, 2025, 6:00 AM EST - 1 year ago

Design Therapeutics Earnings release: Q4 2024


Design Therapeutics Annual report: Q4 2024

Feb 10, 2025, 6:00 AM EST - 1 year ago

Design Therapeutics Annual report: Q4 2024


Design Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Design Therapeutics Quarterly report: Q3 2024


Design Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Design Therapeutics Earnings release: Q3 2024


Design Therapeutics Quarterly report: Q2 2024

Aug 5, 2024, 8:00 AM EDT - 2 years ago

Design Therapeutics Quarterly report: Q2 2024


Design Therapeutics Earnings release: Q2 2024

Aug 5, 2024, 8:00 AM EDT - 2 years ago

Design Therapeutics Earnings release: Q2 2024


Design Therapeutics Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

Design Therapeutics Quarterly report: Q1 2024


Design Therapeutics Earnings release: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

Design Therapeutics Earnings release: Q1 2024


Design Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Design Therapeutics Proxy statement: Proxy Filing


Design Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Design Therapeutics Proxy statement: Proxy Filing


Design Therapeutics Earnings Call Transcript: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Design Therapeutics Earnings Call Transcript: Q4 2023


Design Therapeutics Annual report: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Design Therapeutics Annual report: Q4 2023


Design Therapeutics Earnings release: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Design Therapeutics Earnings release: Q4 2023


Design Therapeutics Quarterly report: Q3 2023

Nov 13, 2023, 8:00 AM EST - 2 years ago

Design Therapeutics Quarterly report: Q3 2023


Design Therapeutics Earnings release: Q3 2023

Nov 13, 2023, 8:00 AM EST - 2 years ago

Design Therapeutics Earnings release: Q3 2023


Design Therapeutics Transcript: Study Update

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Design Therapeutics Transcript: Study Update


Design Therapeutics Slides: Study Update

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Design Therapeutics Slides: Study Update


Design Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Design Therapeutics Quarterly report: Q2 2023


Design Therapeutics Earnings release: Q2 2023

Aug 14, 2023, 8:00 AM EDT - 3 years ago

Design Therapeutics Earnings release: Q2 2023


Design Therapeutics Quarterly report: Q1 2023

May 9, 2023, 8:00 AM EDT - 3 years ago

Design Therapeutics Quarterly report: Q1 2023


Design Therapeutics Earnings release: Q1 2023

May 9, 2023, 8:00 AM EDT - 3 years ago

Design Therapeutics Earnings release: Q1 2023


Design Therapeutics Proxy statement: Proxy Filing

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Design Therapeutics Proxy statement: Proxy Filing


Design Therapeutics Proxy statement: Proxy Filing

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Design Therapeutics Proxy statement: Proxy Filing


Design Therapeutics Annual report: Q4 2022

Mar 14, 2023, 9:00 AM EDT - 3 years ago

Design Therapeutics Annual report: Q4 2022


Design Therapeutics Earnings release: Q4 2022

Mar 14, 2023, 9:00 AM EDT - 3 years ago

Design Therapeutics Earnings release: Q4 2022


Design Therapeutics Quarterly report: Q3 2022

Nov 3, 2022, 9:00 AM EDT - 3 years ago

Design Therapeutics Quarterly report: Q3 2022


Design Therapeutics Earnings release: Q3 2022

Nov 3, 2022, 9:00 AM EDT - 3 years ago

Design Therapeutics Earnings release: Q3 2022


Design Therapeutics Quarterly report: Q2 2022

Aug 8, 2022, 8:00 AM EDT - 4 years ago

Design Therapeutics Quarterly report: Q2 2022


Design Therapeutics Earnings release: Q2 2022

Aug 8, 2022, 8:00 AM EDT - 4 years ago

Design Therapeutics Earnings release: Q2 2022


Design Therapeutics Quarterly report: Q1 2022

May 9, 2022, 8:00 AM EDT - 4 years ago

Design Therapeutics Quarterly report: Q1 2022


Design Therapeutics Earnings release: Q1 2022

May 9, 2022, 8:00 AM EDT - 4 years ago

Design Therapeutics Earnings release: Q1 2022


Design Therapeutics Registration statement: Registration Filing

Apr 27, 2022, 8:00 AM EDT - 4 years ago

Design Therapeutics Registration statement: Registration Filing


Design Therapeutics Proxy statement: Proxy Filing

Apr 27, 2022, 8:00 AM EDT - 4 years ago

Design Therapeutics Proxy statement: Proxy Filing


Design Therapeutics Proxy statement: Proxy Filing

Apr 27, 2022, 8:00 AM EDT - 4 years ago

Design Therapeutics Proxy statement: Proxy Filing


Design Therapeutics Annual report: Q4 2021

Mar 10, 2022, 8:00 AM EST - 4 years ago

Design Therapeutics Annual report: Q4 2021


Design Therapeutics Earnings release: Q4 2021

Mar 10, 2022, 8:00 AM EST - 4 years ago

Design Therapeutics Earnings release: Q4 2021


BioResearcher
BioResearcher Jun. 15 at 5:52 PM
$LRMR LXEO spikes today. FA has a very small market size, but it seems there are more and more companies offer drugs in FA treatment. $LXEO and $DSGN and $BIIB are the 3 companies in addition to LRMR.
0 · Reply
Tripple0toMillion
Tripple0toMillion May. 20 at 10:30 PM
$DSGN $RKLB Rolling my 2k shares profits to $DSGN with PT 17+
0 · Reply
kenny91655
kenny91655 May. 19 at 7:50 PM
$DSGN Love it if it could get down to 7's
0 · Reply
laaarsas
laaarsas May. 19 at 12:49 PM
$DSGN why is stock down?
0 · Reply
SuperGreenToday
SuperGreenToday May. 19 at 12:55 AM
$DSGN Share Price: $10.70 Contract Selected: Dec 18, 2026 $10 Calls Buy Zone: $2.63 – $3.26 Target Zone: $4.47 – $5.46 Potential Upside: 60% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Arcides
Arcides May. 18 at 5:28 PM
$DSGN down 51% from premarket high
1 · Reply
Olivia_Strickland
Olivia_Strickland May. 18 at 4:35 PM
$DSGN down 26% on the morning and my scanner is calling it a "breakout," which at this point I'm just gonna assume is sarcasm. they dropped four-week Friedreich Ataxia data last night and the market's verdict is apparently "thanks but no thanks," because that's a $14 stock trading with a 10 handle on 7.8x avg vol. biotech data prints are the one place where I genuinely have no edge, but I do know what a -26% candle on the news day usually means for the rest of the week. anyone here actually read the readout and have a take on whether this is an overreaction or the start of a longer bleed? structure breaking on the chart: https://tapeboard.com/chart/DSGN?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=dsgn-bk-dn-chart
1 · Reply
Arcides
Arcides May. 18 at 3:43 PM
0 · Reply
laaarsas
laaarsas May. 18 at 3:32 PM
$DSGN Why down today?
0 · Reply
OptionRunners
OptionRunners May. 18 at 12:58 PM
$DSGN +10% on data
0 · Reply
notreload_ai
notreload_ai May. 18 at 12:45 PM
$DSGN DT-216P2 improved Friedreich ataxia symptoms in early trial, increased frataxin levels and was well tolerated with no serious side effects. https://notreload.xyz/xy/dt-216p2-shows-rapid-4-week-gains-in-friedreich-ataxia/
0 · Reply
OpenOutcrier
OpenOutcrier May. 18 at 12:40 PM
$DSGN (+7.9% pre) Design Therapeutics reports positive trial data for Friedreich ataxia drug https://ooc.bz/l/102670
0 · Reply
focafoca99
focafoca99 May. 17 at 10:44 PM
$DSGN hosts a webcast on May 18 to review RESTORE-FA trial data for DT-216P2.
0 · Reply
AlertsAndNews
AlertsAndNews May. 17 at 10:06 PM
$DSGN dropping data tomorrow morning according to the company. Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026 "will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET."
0 · Reply
NVDAMillionaire
NVDAMillionaire May. 14 at 7:49 AM
$DSGN Excellent article that nails exactly where DSGN stands right now. So if you want to update your DSGN knowledge or get acquainted with DSGN, this is a must read. https://everyticker.com/quote/DSGN/analysis/design-therapeutics-platform-validation-at-the-crossroads-of-capital-efficiency-and-clinical-velocity-nasdaq-dsgn
0 · Reply
Doozio
Doozio May. 6 at 6:54 PM
Chop chop huckleberries it was all by $DSGN ONTO 🐒🍌🧠⏰♾️
0 · Reply
OptionRunners
OptionRunners May. 6 at 6:43 PM
$DSGN massive call spread opening. Almost $7M in premium.
1 · Reply
PenkeInvesting
PenkeInvesting May. 4 at 3:09 AM
Fundamental analysis of $DSGN (Design Therapeutics, Inc.) based on financial data and reported results. #DSGN #Design
0 · Reply
StockScanners
StockScanners Apr. 30 at 12:56 AM
$DSGN keep watch if this holds above 15.54
0 · Reply
ScorpionScarlet
ScorpionScarlet Apr. 29 at 7:33 PM
$DSGN what a beast! Up 350% in 1 year! Green non stop! 🥳🥳💕
0 · Reply
RETAlerts
RETAlerts Apr. 29 at 4:23 PM
$DSGN moving on Kaleidescape hardware wins. Strato E and Mini Terra Prime getting recognition is driving real momentum here. Pr...
0 · Reply